The data show that Regorafenib is equivalent to TAS-102 in metastatic CRC.

Published Date: 08 Mar 2023

A real-world comparison showed similar overall survival in patients with refractory metastatic CRC treated with regorafenib or trifluridine/tipiracil (TAS-102).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An Examine More Into the Acceptance of CRISPR/Cas9 Gene Therapy for Sickle Cell Illness.

2.

Slowdown in progress found with cancer survival in England and Wales

3.

Black and Hispanic children with high-risk neuroblastoma have worse outcomes despite standardized treatment

4.

AMA President-Elect Confronts a New Challenge: A Brain Tumor

5.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot